Results 321 to 330 of about 406,491 (336)

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

New England Journal of Medicine, 2019
H. O’sullivan, D. Collins, S. O'Reilly
semanticscholar   +1 more source

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

Cell Metabolism, 2021
Yue Gong, Yun-Song Yang, Tian-Jian Yu
exaly  

Disparities in triple negative breast cancer

Journal of the National Medical Association, 2023
Lisa, Newman, Edith, Mitchell
openaire   +2 more sources

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy

Cell Metabolism, 2023
Yi Xiao
exaly  

Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer

Progress in Materials Science, 2023
Xiangyi Kong, Yihang Qi, Kuo Chu Hwang
exaly  

Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer

Cell, 2021
Fade Gong, Nicholas J Neill, Siddhartha Tyagi   +2 more
exaly  

Chemoimmunotherapy for Triple-Negative Breast Cancer

JAMA, 2018
openaire   +2 more sources

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Nature Medicine, 2019
L. Voorwerk, M. Slagter, H. Horlings, K. Sikorska, K. K. van de Vijver, Michiel de Maaker, I. Nederlof, R. J. Kluin, S. Warren, Sufey Ong, T. Wiersma, N. Russell, F. Lalezari, P. Schouten, N. Bakker, S. Ketelaars, Dennis Peters, C. Lange, E. van Werkhoven, H. van Tinteren, I. Mandjes, I. Kemper, Suzanne Onderwater, M. Chalabi, S. Wilgenhof, J. Haanen, R. Salgado, K. D. de Visser, G. Sonke, L. Wessels, S. Linn, T. Schumacher, C. Blank, M. Kok   +33 more
semanticscholar   +1 more source

Triple-negative breast cancer: disease entity or title of convenience?

Nature Reviews Clinical Oncology, 2010
Lisa A Carey, Eric P Winer, Giuseppe Viale   +2 more
exaly  

Pembrolizumab for triple-negative breast cancer

The Lancet Oncology, 2020
openaire   +2 more sources